Research overview: anti-nerve growth factor therapy for feline osteoarthritis pain

A monoclonal antibody targeting nerve growth factor, a key mediator of chronic pain, was developed as a long-acting injectable treatment for the pain of feline osteoarthritis, offering a novel mechanism distinct from NSAIDs and suited to cats in which traditional analgesics carry risks, especially with concurrent kidney disease. Administered as a monthly injection, it reduces osteoarthritis pain by neutralizing NGF signaling. This overview synthesizes the analgesia literature rather than one citation, describing how anti-NGF antibodies interrupt pain signaling, why a monthly biologic suits the high prevalence of feline osteoarthritis and the limitations of NSAIDs in cats, and how it expanded the options for chronic pain control. It matters because it represents a major advance in managing one of the most common and undertreated sources of chronic pain in older cats.